Replies to post #290133 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

hyperopia,

As Lykiri pointed out, there have been multiple references by Fraunhofer over the years to utilizing an "optimized" L product. Tangential flow filtration is one way this may have been done but Fraunhofer also had a their own cell selection technology that may have been implemented.

Thank you for sharing those links to the new Merck manufacturing facility work. Merck also has a library of tools including monoclonal antibodies which can be used to help activate and mature DCs for many types of disease. All these things combined provide plenty of potential synergy with regard to moving the DCVax platform forward quickly with the right kind of support from regulators with regard to how DC treatments like L and Direct are viewed. If DCs producing specific chemokines/cytokines within a certain range are "the effective treatment" then how you get there should not matter. In other words the end product treatments are "the same". If that is the accepted stand by regulators then Merck and NWBO could be hitting the ground running and be able to stay well ahead of the pack for quite some time.

By the way, my innuendo approach is to encourage others to dig into what's out there. I also use it at times as a type of bait for those who don't look but want to assert certain possibilities don't exist or that the DCVax platform doesn't work. Best wishes.

[hyperopia]

The most important part of the quote from Linda Powers at the Oppenheimer Healthcare Conference got cut off in my response to Doc. Anyway, it’s the second paragraph.

"Now this is the platform technology that I have explained.  It is embodied into two key product lines, two major products. The first one that you see up there, DCVax-L, is for all types of operable tumors, and the second one is for all types of inoperable tumors. Both of the products use the same two key ingredients: that's the immune cell, the dendritic cells themselves, and the biomarkers of the tumor that we want the immune system to hit.  The difference between the two products is just in how we get the biomarker ingredient.  With the product for the operable tumors, when the tumor’s surgically removed in the operating room, they just drop the tissue in a kit and send the kit to us. It literally takes a couple minutes in the operating room.  And then we process it and we get the biomarkers from that tumor tissue.  Well for the inoperable tumors, we don't have the tumor tissue to get the biomarker, so instead we activate the dendritic cells in a little bit different way.  We directly inject them into the tumor, in the body, and the dendritic cells pick up the biomarkers on-site, in the tumor, and from there on out they operate the same, to mobilize the immune system. 
 
And that again brings up one of the key values and competitive strengths of our technology.  Our technology, both products, the one for the operable tumors and the one for the inoperable tumors can apply to any patient.  We are not limited by tumor characteristics and we're not limited by patient characteristics. So we can treat with the same product, made the same way, all of these diverse cancers. That also means that from a regulatory pathway standpoint, after we get the first approval, in the first cancer, each additional cancer is just a label extension. You're not starting all over again with the whole clinical trial pathway. "